Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in moderate-to-severe ulcerative colitis
NCT01482884Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tralokinumab in ulcerative colitis (UC), sponsored by AstraZeneca. Started Mar 2012; status: completed.
02
Drugs
tralokinumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01482884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01482884.